An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Herbert A. Eradat, MD

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Herbert A. Eradat, MD
HS Clinical Professor, Medicine. Authored (or co-authored) 22 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- Links
- Sign up for this study
- ID
- NCT06047080
- Phase
- Phase 3 Lymphoma Research Study
- Study Type
- Interventional
- Participants
- Expecting 1130 study participants
- Last Updated